The global antimalarial drugs market is expected to register lucrative growth over the forecast period 2019-2025. The growth of the market is primarily driven by a substantial increase in malaria-infected persons across the globe. According to the World Health Organization (WHO), an estimated 3.4 billion people in 92 countries are at risk of being infected with malaria and developing a disease, and 1.1 billion are at high risk in 2018. According to the World Malaria Report 2018, there were 219 million cases of malaria globally in 2017 (uncertainty range 203–262 million) and 435,000 mortalities from malaria, representing a decrease in malaria cases and deaths rates of 18% and 28% since 2010, respectively. The burden was heaviest in Africa, where an estimated 93% of all malaria fatalities occurred, and in children aged under 5 years, who accounted for 61% of all mortalities.
Moreover, amidst the recent outbreak of COVID-19, the demand for antimalarial drugs such as hydroxychloroquine is increasing at a rapid pace. The drug shows antiviral activity in vitro against coronaviruses, and specifically, SARS-CoV-2. Owing to the drug effectiveness, various virus affected nations have begun using hydroxychloroquine drug on the affected patients. According to the Worldometers, global coronavirus cases reached over 1.4 million with death toll around 83,000 as of 8th April 2020. With nearly 400,500 infected persons, the US is majorly affected due to the virus spread. The US is followed by Spain and Italy with cases around 146,690 and 135,586 respectively as of 8th April 2020.
The report analyzes the global antimalarial drugs market on the basis of drug class, distribution channel, and geography. Based on drug class, the market is segmented quinine, chloroquine, proguanil, mefloquine, and others. The chloroquine drug class segment is expected to witness the fastest growth in the near terms owing to the wide demand for the drug due to the rapid spread of COVID-19 globally. For instance, on 8th April 2020, the US announced that it has bought over 29 million hydroxychloroquine doses from India. Moreover, Brazil with around 14,000 cases and 688 death tolls has also sought the supply of hydroxychloroquine doses from India. Further, based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and e-commerce.
The global antimalarial drugs market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The market has been segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). RoW region is expected to garner significant revenue over the forecast period due to the rapid surge in the prevalence of malaria in Latin America and the Middle East & Africa. Moreover, Asia-Pacific is expected to register the fastest growth over the forecast period increase in awareness regarding the use of antimalarial drugs for early diagnosis of the infection for better treatment. Further, the market consists of several players that are influencing the global antimalarial drugs industry. Some of the key players of the market include Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Ipca Laboratories Ltd., Merck & Co., Inc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd.
Research Methodology
The study on the antimalarial drugs industry is incorporated by extensive primary and secondary research conducted by the research team. In secondary research, different approaches have been adopted to derive the market value, market growth rate, and analyze trends in the industry due to the COVID-19 pandemic. In the report, the analysis of the country is provided by analyzing various regional players, laws & policies, consumer behavior, macro-economic factors, and impact of the pandemic. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures.
Sources Include
The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Supply & Demand Analysis
3. Market Overview
3.1. Historical market growth estimation in the Antimalarial Drugs Industry not accounting COVID-19 pandemic effect
3.2. Deviations in the Antimalarial Drugs Industry growth rate taking COVID-19 pandemic effect into account
4. Market Segmentation
4.1. Drug Class
4.1.1. Quinine
4.1.2. Chloroquine
4.1.3. Proguanil
4.1.4. Mefloquine
4.1.5. Others (Pyrimethamine)
4.2. Distribution Channel
4.2.1. Hospital Pharmacy
4.2.2. Retail Pharmacy
4.2.3. E-Commerce
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. Rest of Asia-Pacific
5.4. Rest of the World
6. Companies Studied
6.1. Alvizia Healthcare Pvt. Ltd.
6.2. Bayer AG
6.3. F. Hoffmann-La Roche Ltd.
6.4. GlaxoSmithKline PLC
6.5. IPCA Laboratories Ltd.
6.6. Merck & Co., Inc.
6.7. Novartis AG
6.8. Pfizer Inc.
6.9. Sun Pharmaceutical Industries Ltd.
6.10. Cadila Healthcare Ltd.
1. GLOBAL ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
2. GLOBAL QUININE ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
3. GLOBAL CHLOROQUINE ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
4. GLOBAL PROGUANIL ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
5. GLOBAL MEFLOQUINE ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
6. GLOBAL OTHER ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
7. GLOBAL ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2018-2025 ($ MILLION)
8. GLOBAL ANTIMALARIAL DRUGS THROUGH HOSPITAL PHARMACY INDUSTRY RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
9. GLOBAL ANTIMALARIAL DRUGS THROUGH RETAIL PHARMACY INDUSTRY RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
10. GLOBAL ANTIMALARIAL DRUGS THROUGH E-COMMERCE INDUSTRY RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
11. GLOBAL ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
12. NORTH AMERICAN ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
13. NORTH AMERICAN ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
14. NORTH AMERICAN ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2018-2025 ($ MILLION)
15. EUROPEAN ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
16. EUROPEAN ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
17. EUROPEAN ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2018-2025 ($ MILLION)
18. ASIA-PACIFIC ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
19. ASIA-PACIFIC ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
20. ASIA-PACIFIC ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2018-2025 ($ MILLION)
21. REST OF THE WORLD ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
22. REST OF THE WORLD ANTIMALARIAL DRUGS INDUSTRY RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2018-2025 ($ MILLION)
1. GLOBAL ANTIMALARIAL DRUGS INDUSTRY TREND PRE AND POST COVID-19, 2019-2025 (%)
2. NORTH AMERICAN ANTIMALARIAL DRUGS INDUSTRY TREND PRE AND POST COVID-19, 2019-2025 (%)
3. EUROPEAN ANTIMALARIAL INDUSTRY TREND PRE AND POST COVID-19, 2019-2025 (%)
4. ASIA-PACIFIC ANTIMALARIAL DRUGS INDUSTRY TREND PRE AND POST COVID-19, 2019-2025 (%)
5. REST OF THE WORLD ANTIMALARIAL DRUGS INDUSTRY TREND PRE AND POST COVID-19, 2019-2025 (%)